Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Vehicle-controlled, Phase I Study to Evaluate Safety and Efficacy of a 0.3% and 1% Topical Formulation of KM-001 for Management of Moderate to Severe Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)

NCT05454462 is registered in ClinicalTrials.gov with Orvida Pharma (formerly Kamari Pharma) as lead sponsor.

NCT NCT05454462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05454462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Vehicle-controlled, Phase I Study to Evaluate Safety and Efficacy of a 0.3% and 1% Topical Formulation of KM-001 for Management of Moderate to Severe Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)
Lead sponsor
Orvida Pharma (formerly Kamari Pharma)
Phase
Phase 1
Overall status
Completed
Start date
May 24, 2022
Completion date
April 4, 2023
Enrollment
55 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lichen simplex chronicus